Mesenchymal stem cells that located in the electromagnetic fields improves rat model of Parkinson's disease

Mesenchymal stem cells that located in the electromagnetic fields improves rat model of Parkinson's disease

Objective(s): The main characteristic of mesenchymal stem cells (MSCs) is their ability to produce other cell types. Electromagnetic field (EMF) stimulates differentiation of MSCs into other cells. In this study, we investigated whether EMF can effect on the differentiation of MSCs into dopaminergic...

Full description

Bibliographic Details
Main Authors:	Majid Jadidi, Saeed Moghadas Biat, Hamid Reza Sameni, Manouchehr Safari, Abbas Ali Vafaei, Laya Ghahari
Format:	Article
Language:	English
Published:	Mashhad University of Medical Sciences 2016-07-01
Series:	Iranian Journal of Basic Medical Sciences
Subjects:	Dopaminergic neuron Electromagnetic field Mesenchymal stem cells Parkinson’s disease
Online Access:	http://ijbms.mums.ac.ir/article_7358_2eae75e9bb96b343a7bf8de4579c873c.pdf

Similar Items

G-CSF for mobilizing transplanted bone marrow stem cells in rat model of Parkinson's disease
by: Manouchehr Safari, et al.
Published: (2016-12-01)

Intravenous Transplantation of Adipose-Derived Mesenchymal Stem Cells Promoted The Production of Dopaminergic Neurons and Improved Spatial Memory in A Rat Model of Parkinson’s Disease
by: Helia Hamedi, et al.
Published: (2023-05-01)

Studying the Pathophysiology of Parkinson’s Disease Using Zebrafish
by: Lisa M. Barnhill, et al.
Published: (2020-07-01)

Roles of stem cells in the treatment of Parkinson's disease
by: Yasaman Ebrahimikia, et al.
Published: (2018-10-01)

Mesenchymal Stem Cells with Granulocyte Colony-Stimulating Factor Reduce Stress Oxidative Factors in Parkinson\'s Disease
by: Laya Ghahari, et al.
Published: (2020-03-01)

Excessive Daytime Sleepiness in Parkinson’s Disease
by: Liu H, et al.
Published: (2022-09-01)

Current status of stem cell-derived therapies for Parkinson’s disease : from cell assessment and imaging modalities to clinical trials
by: Jang, Se Eun, et al.
Published: (2021)

Animal Models of Autosomal Recessive Parkinsonism
by: Guendalina Bastioli, et al.
Published: (2021-07-01)

A Focus on Astrocyte Contribution to Parkinson’s Disease Etiology
by: Giselle Prunell, et al.
Published: (2022-11-01)

Parkinson’s disease: general features, effects of levodopa treatment and future directions
by: Marco Aurelio M Freire, et al.
Published: (2010-11-01)

Celastrol Inhibits Dopaminergic Neuronal Death of Parkinson’s Disease through Activating Mitophagy
by: Ming-Wei Lin, et al.
Published: (2019-12-01)

Mitochondrial Phenotypes in Parkinson’s Diseases—A Focus on Human iPSC-Derived Dopaminergic Neurons
by: Leonie M. Heger, et al.
Published: (2021-12-01)

Irisin protect the Dopaminergic neurons of the Substantia nigra in the rat model of Parkinson’s disease
by: Sam Zarbakhsh, et al.
Published: (2019-07-01)

Brain‐derived neurotrophic factor attenuates cognitive impairment and motor deficits in a mouse model of Parkinson's disease
by: E Chang, et al.
Published: (2021-08-01)

Neuroprotective potential of Afzelin: A novel approach for alleviating catalepsy and modulating Bcl-2 expression in Parkinson's disease therapy
by: Khalid M. Alharthy, et al.
Published: (2024-02-01)

Genetic Imaging of Neuroinflammation in Parkinson’s Disease: Recent Advancements
by: Longping Yao, et al.
Published: (2021-07-01)

The Molecular Mechanisms of the Relationship between Insulin Resistance and Parkinson’s Disease Pathogenesis
by: Viviana A. Ruiz-Pozo, et al.
Published: (2023-08-01)

TFE3-Mediated Autophagy is Involved in Dopaminergic Neurodegeneration in Parkinson’s Disease
by: Xin He, et al.
Published: (2021-11-01)

Understanding miRNA Based Gene Regulation in Parkinson’s Disease: An in silico Approach
by: Surya Narayan Rath, et al.
Published: (2020-03-01)

Neuron-Astrocyte Interactions in Parkinson’s Disease
by: Ikuko Miyazaki, et al.
Published: (2020-12-01)

Caffeic Acid Phenethyl Ester With Mesenchymal Stem Cells Improves Behavioral and Histopathological Changes in the Rat Model of Parkinson Disease
by: Khojasteh Rahimi Jaberi, et al.
Published: (2022-09-01)

The Relationship between Iron and LRRK2 in a 6-OHDA-Induced Parkinson’s Disease Model
by: Ruru Jia, et al.
Published: (2023-02-01)

Modeling of the Progressive Degradation of the Nigrostriatal Dopaminergic System in Mice to Study the Mechanisms of Neurodegeneration and Neuroplasticity in Parkinson’s Disease
by: Anna Kolacheva, et al.
Published: (2022-12-01)

Triggering Receptor Expressed on Myeloid Cells 2 Protects Dopaminergic Neurons by Promoting Autophagy in the Inflammatory Pathogenesis of Parkinson’s Disease
by: Wei Huang, et al.
Published: (2021-11-01)

Downregulation of Ambra1 by altered DNA methylation exacerbates dopaminergic neuron damage in a fenpropathrin-induced Parkinson-like mouse model
by: Songzhe He, et al.
Published: (2024-02-01)

Neuroprotective effects of osmotin in Parkinson’s disease-associated pathology via the AdipoR1/MAPK/AMPK/mTOR signaling pathways
by: Jun Sung Park, et al.
Published: (2023-08-01)

A novel curcumin oil solution can better alleviate the motor activity defects and neuropathological damage of a Parkinson’s disease mouse model
by: Xiwen Geng, et al.
Published: (2022-07-01)

The Role of Non-Coding RNAs in the Pathogenesis of Parkinson’s Disease: Recent Advancement
by: Hanwen Zhang, et al.
Published: (2022-06-01)

miR-100a-5p-enriched exosomes derived from mesenchymal stem cells enhance the anti-oxidant effect in a Parkinson’s disease model via regulation of Nox4/ROS/Nrf2 signaling
by: Songzhe He, et al.
Published: (2023-10-01)

Searching for Biomarkers in the Blood of Patients at Risk of Developing Parkinson’s Disease at the Prodromal Stage
by: Elena A. Katunina, et al.
Published: (2023-01-01)

Combining Gene Transfer and Nonhuman Primates to Better Understand and Treat Parkinson’s Disease
by: Christelle Lasbleiz, et al.
Published: (2019-02-01)

Neuroprotective Effects of the DPP4 Inhibitor Vildagliptin in In Vivo and In Vitro Models of Parkinson’s Disease
by: Ramesh Pariyar, et al.
Published: (2022-02-01)

Inhibition of Calpain Attenuates Degeneration of Substantia Nigra Neurons in the Rotenone Rat Model of Parkinson’s Disease
by: Vandana Zaman, et al.
Published: (2022-11-01)

Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson’s disease animal model
by: Atsushi Fujita, et al.
Published: (2018-08-01)

Dopamine transporter neuroimaging accurately assesses the maturation of dopamine neurons in a preclinical model of Parkinson’s disease
by: Julian L. Goggi, et al.
Published: (2020-08-01)

The role of NURR1 in metabolic abnormalities of Parkinson’s disease
by: Murad Al-Nusaif, et al.
Published: (2022-06-01)

Roles of FGF20 in dopaminergic neurons and Parkinson’s disease
by: Nobuyuki eItoh, et al.
Published: (2013-05-01)

Curcumin-Loaded Human Serum Albumin Nanoparticles Prevent Parkinson’s Disease-like Symptoms in <i>C. elegans</i>
by: Arvie Camille V. de Guzman, et al.
Published: (2022-02-01)

Degeneration of dopaminergic neurons due to metabolic alterations and Parkinson’s disease
by: Juhyun eSong, et al.
Published: (2016-03-01)

GDNF signaling in subjects with minimal motor deficits and Parkinson's disease
by: Yaping Chu, et al.
Published: (2021-06-01)